XML 110 R95.htm IDEA: XBRL DOCUMENT
v3.22.2.2

SEGMENT INFORMATION - Disaggregation of Revenue (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 2,046 | $ 2,111 | $ 5,931 | $ 6,238
Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 942 | 941 | 2,670 | 2,775
Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 462 | 469 | 1,369 | 1,393
OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 402 | 409 | 1,177 | 1,115
Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 220 | 269 | 655 | 884
Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 20 | 23 | 60 | 71
Salix |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 544 | 527 | 1,509 | 1,515
Salix | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 543 | 525 | 1,508 | 1,509
Salix | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Salix | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 1 | 2 | 1 | 6
International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 250 | 271 | 727 | 890
International | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 72 | 61 | 206 | 187
International | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
International | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 38 | 41 | 111 | 98
International | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 131 | 161 | 386 | 579
International | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 9 | 8 | 24 | 26
Solta Medical |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 72 | 74 | 201 | 219
Solta Medical | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Solta Medical | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 72 | 74 | 201 | 219
Solta Medical | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Solta Medical | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Solta Medical | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 |  | 0
Diversified Products |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 238 | 290 | 722 | 850
Diversified Products | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 206 | 234 | 608 | 699
Diversified Products | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 0 | 0 | 0 | 0
Diversified Products | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 2 | 3 | 5 | 7
Diversified Products | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 24 | 47 | 91 | 125
Diversified Products | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 6 | 6 | 18 | 19
Bausch + Lomb |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 942 | 949 | 2,772 | 2,764
Bausch + Lomb | Pharmaceuticals |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 121 | 121 | 348 | 380
Bausch + Lomb | Devices |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 390 | 395 | 1,168 | 1,174
Bausch + Lomb | OTC |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 362 | 365 | 1,061 | 1,010
Bausch + Lomb | Branded and Other Generics |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 65 | 61 | 178 | 180
Bausch + Lomb | Other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 4 | $ 7 | $ 17 | $ 20

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_PharmaceuticalProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_DeviceProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OvertheCounterProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_BrandedandOtherGenericProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=bhc_OtherRevenuesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SalixSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_InternationalRxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_SoltaMedicalSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_DiversifiedProductsSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=bhc_BauschLombMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |